Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Trial ID or NCT#

NCT03045328,,

Status

not recruiting iconNOT RECRUITING

Purpose

This is an open-label non-randomized two-center phase 2 study evaluating the safety and efficacy of concurrent therapy with ibrutinib and venetoclax in subjects with relapsed or refractory CLL/SLL.

Official Title

An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

David Iberri
David Iberri
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Hematology
Jason R Gotlib
Hematologist-Oncologist
Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov